Related Experiment Video
Updated: Aug 5, 2026
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Advancing stroke safety and efficacy through early tirofiban administration after intravenous thrombolysis: The
Chunrong Tao1, Tianlong Liu1, Jun Sun1
1Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Background:
Intravenous thrombolysis (IVT) is the cornerstone treatment for the acute ischemic stroke (AIS) within 4.5 h after onset. Current guidelines recommend administering antiplatelet medications 24 h after IVT. However, vascular reocclusion is a common occurrence after IVT. Tirofiban, a platelet glycoprotein IIb/IIIa antagonist, can help deter macrovascular reocclusion, prevent microvascular thrombosis, and enhance cerebral blood flow.
Objective:
This trial aims to assess whether early administration of tirofiban can improve clinical outcomes in patients with AIS who received IVT.
Methods And Design:
The Advancing Stroke Safety and Efficacy through Early Tirofiban Administration after Intravenous Thrombolysis (ASSET IT) Trial is an investigator-initiated, randomized, placebo-controlled, double-blind, multicenter study. Up to 832 eligible patients will be consecutively randomized in a 1:1 ratio to receive either intravenous tirofiban or placebo over a period of 2 years across 38 stroke centers in China.
Outcomes:
The primary endpoint is excellent functional status at day 90, defined as a modified Rankin Score of 0-1. Primary safety endpoints include symptomatic intracerebral hemorrhage at 24 h and mortality at 90 days.
Trial Registry Number:
NCT06134622 (clinicaltrials.gov).
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:22Heart Failure Drugs: β-Blockers
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
01:22Heart Failure VI: Adjunct Therapies